FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)
-
-
-
-
-
-
-
Invivyd begins Phase 3 trial comparing COVID antibody to mRNA vaccine
-
-
-
-
-
-
-
Invivyd publishes research comparing COVID antibody to vaccine side effects
-
-
-
-
-
-
-
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
-
-
-
-
-
-
-
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
-
-
-
-
-
-
-
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
-
330,680 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

